Patents Examined by Kevin E. Weddington
  • Patent number: 10292950
    Abstract: Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: May 21, 2019
    Assignee: Pathologica LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Patent number: 10272080
    Abstract: Working memory deficits are treated and working memory is improved with a composition that comprises a therapeutically effective amount of one or more respective selective dopamine D4 receptor agonists and/or pharmaceutically acceptable analogs, salts or hydrates of the respective one or more selective dopamine D4 receptor agonists. This composition can be administered to a subject to improve the subject's working memory.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: April 30, 2019
    Assignees: Florida State University Research Foundation, Inc., The General Hospital Corporation
    Inventors: Pradeep G. Bhide, Jinmin Zhu, Joseph Biederman, Thomas J. Spencer
  • Patent number: 10265314
    Abstract: The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors (PDE5i) in combination with a) treatments, leading to increased cGMP mobilization, and/or b) tretaments correcting and/or potentiatiating CFTR function, and/or c) treatments currently used as standard of care in Cystic Fibrosis, and/or d) antinflammatory treatments for the preparation of medicaments for the treatment of Cystic Fibrosis (CF) with improved efficacy over methods of treatments already known.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: April 23, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter Sandner, Johannes-Peter Stasch, Michael Hahn, Markus Follmann
  • Patent number: 10265300
    Abstract: Methods of treating a seizure disorder with a maxi-K channel opener or a pharmaceutically acceptable salt thereof are provided. In embodiments, suitable maxi-K channel openers are be fluoro-oxindole or chloro-oxindole compounds. In some embodiments, the maxi-K channel opener may be (3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6 -(trifluoromethyl)-2H-indole-2-one or pharmaceutically acceptable salts thereof. The methods provide therapeutic compositions that may be used to improve one or more symptoms of a seizure disorder.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: April 23, 2019
    Assignee: OVID THERAPEUTICS INC.
    Inventor: Matthew During
  • Patent number: 10265343
    Abstract: The present invention relates to methods of co-administration of various vitamins and mineral compositions, and in a specific embodiment, said methods comprise co-administering one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and a second composition comprising omega-3 fatty acids such as DHA, to supplement the nutritional needs of individuals within physiologically stressful states; and kits provided for co-administration of various vitamin and mineral compositions, and in a specific embodiment, said kits comprise one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and a second composition comprising omega-3 fatty acids, such as DHA, to supplement the nutritional needs of individuals within physiologically stressful states.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: April 23, 2019
    Assignee: Exeltis USA, Inc.
    Inventors: John A. Giordano, Charles J. Balzer
  • Patent number: 10265287
    Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: April 23, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Patent number: 10259835
    Abstract: Compounds having the following structure (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of R1, R2 or R3 is —P(?O)(OH)2, and the other two of R1, R2 and R3 are each H, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: April 16, 2019
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Adam Siddiqui-Jain, David J. Bearss
  • Patent number: 10251886
    Abstract: a pharmaceutical composition for preventing, treating, or ameliorating one or more symptoms of a malignant tumor associated with EGFR mutation and/or K-RAS mutation is provided. The pharmaceutical composition includes a 4-anilinoquinazoline derivative having a formula (I) where A is iodine when m is 1 and n is zero, or A is albumin when m is an integral ranging from 1 to 7 and n is 1.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: April 9, 2019
    Assignee: National Chiao Tung University
    Inventors: Jui-I Chao, Chin-Piao Chen, Kuang-Kai Liu
  • Patent number: 10251860
    Abstract: Disclosed herein are embodiments of a method of accelerating bone healing in a subject in need thereof, comprising administering to the subject a compound disclosed here. The method may further comprise selecting or identifying a subject that has bone damage, or is a risk of developing bone damage. The compound may be administered after bone damage has occurred, or it may be administered prophylactically. The compound may be administered to a subject that has not and/or will not be exposed to radiation. In other embodiments, the subject has been and/or will be exposed to radiation.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: April 9, 2019
    Assignees: University of Pittsburgh—of the Commonwealth System of Higher Education, The Brigham and Women's Hospital, Inc.
    Inventors: Michael W. Epperly, Joel S. Greenberger, Peter Wipf, Julianne Glowacki
  • Patent number: 10251883
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: April 9, 2019
    Assignee: Melior Pharmaceuticals I, Inc.
    Inventors: Andrew G. Reaume, Michael S. Saporito
  • Patent number: 10238689
    Abstract: The present disclosure provides a method for killing persister cells with mitomycin C and/or cisplatin, or derivatives thereof. Recalcitrant infections are difficult to treat due to persister cells, a subpopulation of all bacterial populations that is highly tolerant against all traditional antibiotics since the cells are dormant and antibiotics are designed to kill growing cells. Here, we show that MMC and cisplatin eradicate persister cells through a growth-independent mechanism, cross-linking DNA. We find both agents are effective against both planktonic cultures and highly robust biofilm cultures for a broad range of bacterial species, including commensal Escherichia coli K-12 as well as pathogenic species of E. coli, Staphylococcus aureus, and Pseudomonas aeruginosa. In certain approaches cisplatin is superior to MMC.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: March 26, 2019
    Assignee: The Penn State Research Foundation
    Inventors: Thomas Wood, Brian Kwan, Nityananda Chowdhury
  • Patent number: 10238647
    Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: March 26, 2019
    Assignee: Nalpropion Pharmaceuticals, Inc.
    Inventors: Eckard Weber, Michael Alexander Cowley
  • Patent number: 10238673
    Abstract: The present invention includes compositions and methods for treating certain conditions such as dry eye or dry mouth with a comprising a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine, wherein the composition is provided in an amount sufficient to treat dry eye or dry mouth.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: March 26, 2019
    Assignee: GENETIC DISEASE INVESTIGATORS, LLC
    Inventor: Diana Driscoll
  • Patent number: 10238653
    Abstract: This invention relates to methods and formulations for treating metabolic disorders and depression. In some embodiments, the methods comprise administering a dopamine receptor agonist and an anti-depressant.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: March 26, 2019
    Assignee: VeroScience LLC
    Inventor: Anthony H. Cincotta
  • Patent number: 10238662
    Abstract: The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: March 26, 2019
    Assignee: ANTARES PHARMA, INC.
    Inventors: Paul K. Wotton, Hermanus L. Jooste, Kaushik J. Dave, Jon Jaffe
  • Patent number: 10232049
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: March 19, 2019
    Assignee: MADRIGAL PHARMACEUTICALS, INC.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying
  • Patent number: 10231963
    Abstract: The present application relates methods for treating a depressive symptom comprising administering an effective amount of a ? opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: March 19, 2019
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Laura Cook Blumberg, Daniel R. Deaver, David J. Eyerman, Thomas Andrew Wynn
  • Patent number: 10231943
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: March 19, 2019
    Assignee: Infirst Healthcare Limited
    Inventors: Robin Mark Bannister, John Brew, Suzanne Jane Dilly, Gregory Alan Stoloff, Wilson Caparros Wanderley
  • Patent number: 10226435
    Abstract: The present invention provides methods of treating humans and animals with terpenes and terpenoids in order to restore the stratum granulosum and stratum corneum and treat a dermatological disease, such as, for instance atopic dermatitis. More specifically it provides terpenes and terpenoids such as monoterpenoids, sesquiterpenes and norisoprenoids as ingredients that work to restore and thicken the stratum granulosum and stratum corneum and treat a dermatological disease. Terpenes and terpenoid compounds support the cell proliferation, cell differentiation, growth of skin, skin tissue and keratinocytes by upregulating genes for loricrin filaggrin, caspase 14, hornerin and other late cornified envelope components and vascular endothelial growth factor (VEGF) and downregulation of matrix metalloproteinases. Both terpenes and terpenoids may be applied topically or orally at oral or topical concentrations from about 0.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: March 12, 2019
    Assignees: New York University, BIOKEYS FOR FLAVORS, LLC
    Inventors: Fredric J. Burns, Ivica Labuda
  • Patent number: 10220013
    Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: March 5, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku